To date, only one review has delved into the role of B2M in cancer immunotherapy, highlighting that B2M alterations are prevalent across various cancers and are linked to tumor immune escape and immunotherapy resistance, and may serve as a potential biomarker for ICIs treatment (27). Here, B2M is linked to neoplasm.